← ACADIA PHARMACEUTICALS INC ACAD
Market Price
$28.23
Market Cap
$4.86B
P/E Ratio
12.28
Revenue (FY 2025)
↑11.9% YoY
$1.07B
3-Yr CAGR: 27.5%
Net Income
↑72.7% YoY
$391.00M
Net Margin: 36.5%
Free Cash Flow
↓-33.1% YoY
$105.15M
FCF Yield: 2.16%
EPS (Diluted)
↑69.1% YoY
$2.30
Basic: $2.32
Return on Equity
Efficiency
31.9%
ROA: 36.8%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ACAD)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $17.3M | — | $14.3M | $-271.4M | — | $-2.34 | — | $-208.4M | $-209.9M | — |
| FY 2017 | $124.9M | +620.7% | $115.8M | $-289.4M | -6.6% | $-2.36 | -0.9% | $-217.8M | $-218.6M | -4.1% |
| FY 2018 | $223.8M | +79.2% | $18.3M | $-245.2M | +15.3% | $-1.94 | +17.8% | $-167.5M | $-169.6M | +22.4% |
| FY 2019 | $339.1M | +51.5% | $327.7M | $-235.3M | +4.1% | $-1.60 | +17.5% | $-151.1M | $-152.3M | +10.2% |
| FY 2020 | $441.8M | +30.3% | $431.5M | $-281.6M | -19.7% | $-1.79 | -11.9% | $-136.2M | $-143.8M | +5.6% |
| FY 2021 | $484.1M | +9.6% | $473.3M | $-167.9M | +40.4% | $-1.05 | +41.3% | $-125.7M | $-126.8M | +11.8% |
| FY 2022 | $517.2M | +6.8% | $507.1M | $-216.0M | -28.7% | $-1.34 | -27.6% | $-114.0M | $-114.0M | +10.1% |
| FY 2023 | $726.4M | +40.4% | $684.8M | $-61.3M | +71.6% | $-0.37 | +72.4% | $16.7M | $16.7M | +114.6% |
| FY 2024 | $957.8M | +31.8% | $876.0M | $226.5M | +469.5% | $1.36 | +467.6% | $157.7M | $157.2M | +844.0% |
| FY 2025 | $1,071.5M | +11.9% | $982.5M | $391.0M | +72.7% | $2.30 | +69.1% | $109.8M | $105.1M | -33.1% |
Valuation
Market Price
$28.23
Market Cap
$4.86B
Enterprise Value
N/A
P/E Ratio
12.28
P/B Ratio
3.94
FCF Yield
2.16%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
91.69%
Operating Margin
9.78%
Net Margin
36.49%
Return on Equity (ROE)
31.86%
Return on Assets (ROA)
36.81%
Asset Turnover
1.01x
Revenue 3-Yr CAGR
27.48%
Financial Health & Liquidity
Current Ratio
3.99
Cash Ratio
0.67
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$177.69M
Total Debt
N/A
Book Value / Share
$7.17
Cash Flow Efficiency
Operating Cash Flow
$109.84M
Capital Expenditures (CapEx)
$4.69M
Free Cash Flow
$105.15M
OCF / Revenue
10.25%
FCF / Revenue
9.81%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$2.30
EPS (Basic)
$2.32
Dividends / Share
N/A
Book Value / Share
$7.17
EPS YoY Growth
69.12%
Balance Sheet (FY 2025)
Total Assets
$1.06B
Total Liabilities
$266.21M
Stockholders' Equity
$1.23B
Current Assets
$1.06B
Current Liabilities
$266.21M